- AI-screener
- Securities US
- Merck & Company, Inc.
Merck & Company, Inc.
$79.00
$1.35
1.74%
6 Jun 20:00
$73.31
$134.63
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
bullish sentiment is waning
3day with a yield of0.89%
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
Sentiment
BullishStart Date
06.06.2025Duration
0Yield
0.00%Avg.Yield
-8.24%
Volatility
2.29%Max MDD
Avg. MDD
-13.66%Min Price
RUB 78.97Max Price
RUB 78.97
Protective stop levels
S/L 5%RUB 81.50 | S/L 10%RUB 85.38 | S/L 15%RUB 89.26 | |
|---|---|---|---|
Day | 3.20% | 0.00% | 0.00% |
Week | 33.77% | 6.11% | 0.60% |
Month | 63.99% | 36.08% | 18.02% |
Technical analysis
- Trend ClassLinear Down
- Trend PowerStrong trend
- PatternDescending Wedge
- EMA-20Bearish reversal2025-05-06 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-50Bearish reversal2025-03-21 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-1002024-07-12 the price crossed down the moving average line and demonstrates a downside trend.
- StochasticBearishThe stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: signal line crossed the middle level.
- RSIBearish recoveryRSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.
- MACDBearish recoveryOscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.
- Candle pattern typeLong Leggedconsists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 0.04% | 2.64% | $78.21 | $79.49 | 491.91M |
| Week | 2.81% | 3.10% | $75.40 | $79.49 | 4.64B |
| Month | -0.15% | 0.45% | $73.31 | $81.27 | 18.23B |
| 3 Months | -16.53% | 0.82% | $73.31 | $97.37 | 50.26B |
| 6 Months | -23.35% | 16.34% | $73.31 | $105.07 | 93.86B |
| Year | -39.54% | 0.64% | $73.31 | $134.63 | 165.59B |
| 3 years | -12.68% | 75.95% | $73.31 | $134.63 | 402.88B |
| 5 years | 0.62% | 100.06% | $68.49 | $134.63 | 707.63B |
| All time | 102.22% | 81.24% | $19.15 | $134.63 | 670.15B |
Volatility
| MRK | By industry | |
|---|---|---|
| Yesterday | 23.09% | 1.28% |
| Week | 1.60% | 7.29% |
| Month | 7.04% | 10.86% |
| 3 Months | 13.69% | 20.88% |
| 6 Months | 16.63% | 29.79% |
| Year | 27.62% | 39.37% |
| 3 years | 38.99% | 85.40% |
| 5 years | 50.01% | 115.71% |
| All time | — | — |
- Sortino
- -1.11
- Sharpe
- -1.49
- Sterling
- -0.92
- Liquidity index
- 7.38
- Alpha
- 0.00129
- Beta
- 0.29
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$198.30B
Capitalization
2.51B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US58933Y1055
ISIN
100
Lot size
Mr. Robert M. Davis J.D.
CEO
Website
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.